Identification of the Interleukin 4 Receptor α Gene as a Direct Target for p73

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8145-8152

  Sasaki, Yasushi ^a   Mita, Hiroaki ^a   Toyota, Minoru ^a   Ishida, Setsuko ^a   Morimoto, Ichiro ^a   Yamashita, Toshiharu ^a   Tanaka, Toshihiro ^b   Imai, Kohzoh ^a   Nakamura, Yusuke ^b   Tokino, Takashi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN RECEPTOR; PROTEIN P300; PROTEIN P53; PROTEIN P73; RECOMBINANT INTERLEUKIN 4; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE; GENE IDENTIFICATION; GENE INDUCTION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTERLEUKIN 4 RECEPTOR ALPHA GENE; MULTIGENE FAMILY; NERVOUS SYSTEM DEVELOPMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DNA BINDING; SENSORY SYSTEM; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

ACETYLATION; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CISPLATIN; CONSENSUS SEQUENCE; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HISTONES; HUMANS; INTERLEUKIN-4; INTRONS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); RECEPTORS, INTERLEUKIN-4; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 10744232289     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. El-Deiry, W. S. Regulation of p53 downstream genes. Semin. Cancer Biol., 8: 345-357, 1998.
2. Tokino, T., and Nakamura, Y. The role of p53-target genes in human cancer. Crit. Rev. Oncol. Hematol., 33: 1-6, 2000.
3. Vogelstein, B., Lane, D., and Levine, A. J. Surfing the p53 network. Nature (Lond.), 408: 307-310, 2000.
4. Sharpless, N. E., and DePinho, R. A. p53: good cop/bad cop. Cell, 110: 9-12, 2002.
5. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90: 809-819, 1997.
6. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dotsch, V., Andrews, N. C., Caput, D., and McKeon, F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell, 2: 305-316, 1998.
7. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., and Ikawa, S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med., 4: 839-843, 1998.
8. Jost, C. A., Marin, M. C., and Kaelin, W. G., Jr. p73 is a human p53-related protein that can induce apoptosis. Nature (Lond.), 389: 191-194, 1997.
9. Yang, A., Kaghad, M., Caput, D., and McKeon, F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet., 18: 90-95, 2002.
10. Irwin, M. S., and Kaelin, W. G. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ., 12: 337-349, 2001.
11. Yang, A., and McKeon, F. P63 and P73: P53 mimics, menaces and more. Nat. Rev. Mol. Cell. Biol., 1: 199-207, 2000.
12. Melino, G., De Laurenzi, V., and Vousden, K. H. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer, 2: 605-615, 2002.
13. Hollstein, M., Hergenhahn, M., Yang, Q., Bartsch, H., Wang, Z. Q., and Hainaut, P. New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res., 431: 199-209, 1999.
14. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
15. Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., McKeon, F., and Caput, D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature (Lond.), 404: 99-103, 2000.
16. Zheng, X., and Chen, X. Aquaporin 3, a glycerol and water transporter, is regulated by p73 of the p53 family. FEBS Lett., 489: 4-7, 2001.
17. Blint, E., Phillips, A. C., Kozlov, S., Stewart, C. L., and Vousden, K. H. Induction of p57(KIP2) expression by p73β. Proc. Natl. Acad. Sci. USA, 99: 3529-3534, 2002.
18. Shinbo, J., Ozaki, T., Nakagawa, T., Watanabe, K., Nakamura, Y., Yamazaki, M., Moriya, H., Nakagawara, A., and Sakiyama, S. p73-dependent expression of DAN during eisplatin-induced cell death and osteoblast differentiation. Biochem. Biophys. Res. Commun., 295: 501-507, 2002.
19. Ishida, S., Yamashita, T., Nakaya, U., and Tokino, T. Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. Jpn. J. Cancer Res., 91: 174-180, 2000.
20. Sasaki, Y., Morimoto, I., Ishida, S., Yamashita, T., Imai, K., and Tokino, T. Adenovirus-mediated transfer of the p53 family genes, p73 and p51/ p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of colorectal cancer. Gene Ther., 8: 1401-1408, 2001.
21. Ono, K., Tanaka, T., Tsunoda, T., Kitahara, O., Kihara, C., Okamoto, A., Ochiai, K., Takagi, T., and Nakamura, Y. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res., 60: 5007-5011, 2000.
22. Nishimori, H., Sasaki, Y., Yoshida, K., Irifune, H., Zembutsu, H., Tanaka, T., Aoyama, T., Hosaka, T., Kawaguchi, S., Wada, T., Hata, J., Toguchida, J., Nakamura, Y., and Tokino, T. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene, 21: 8302-8309, 2002.
23. Watanabe, G., Nishimori, H., Irifune, H., Sasaki, Y., Ishida, S., Zembutsu, H., Tanaka, T., Kawaguchi, S., Wada, T., Hata, J., Kusakabe, M., Yoshida, K., Nakamura, Y., and Tokino, T. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes. Genes Chromosomes Cancer, 36: 224-232, 2003.
24. Sasaki, Y., Ishida, S., Morimoto, I., Yamashita, T., Kojima, T., Kihara, C., Tanaka, T., Imai, K., Nakamura, Y., and Tokino, T. The p53 family member genes are involved in the Notch signal pathway. J. Biol. Chem., 277: 719-724, 2002.
25. Morimoto, I., Sasaki, Y., Ishida, S., Imai, K., and Tokino, T. Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer, 33: 270-278, 2002.
26. Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., and Kaelin, W. G. Chemosensitivity linked to p73 function. Cancer Cell, 3: 403-410, 2003.
27. Prabhu, N. S., Somasundaram, K., Satyamoorthy, K., Herlyn, M., and El-Deiry, W. S. p73β, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int. J. Oncol., 13: 5-9, 1998.
28. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. Definition of a consensus binding site for p53. Nat. Genet., 1: 45-49, 1992.
29. Tokino, T., Thiagalingam, S., El-Deiry, W. S., Waldman, T., Kinzler, K. W., and Vogelstein, B. p53 tagged sites from human genomic DNA. Hum. Mol. Genet., 3: 1537-1542, 1994.
30. Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G., Jr., Levrero, M., and Wang, J. Y. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (Lond.), 399: 806-809, 1999.
31. Agami, R., Blandino, G., Oren, M., and Shaul, Y. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature (Lond.), 399: 809-813, 1999.
32. Yuan, Z. M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y. Y., Lu, H., Kharbanda, S., Weichselbaum, R., and Kufe, D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (Lond.), 399: 814-817, 1999.
33. Corn, P. G., Kuerbitz, S. J., van Noesel, M. M., Esteller, M., Compitello, N., Baylin, S. B., and Herman, J. G. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res., 59: 3352-3356, 1999.
34. Chen, C. L., Ip, S. M., Cheng, D., Wong, L. C., and Ngan, H. Y. P73 gene expression in ovarian cancer tissues and cell lines. Clin. Cancer Res., 6: 3910-3915, 2000.
35. Dong, S., Pang, J. C., Hu, J., Zhou, L. F., and Ng, H. K. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int. J. Cancer, 98: 370-375, 2002.
36. Araki, D., Uzawa, K., Watanabe, T., Shiiba, M., Miyakawa, A., Yokoe, H., and Tanzawa, H. Frequent allelic losses on the short arm of chromosome 1 and decreased expression of the p73 gene at 1p36.3 in squamous cell carcinoma of the oral cavity. Int. J. Oncol., 20: 355-360, 2002.
37. Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., and Berger, S. L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell, 8: 1243-1254, 2001.
38. Espinosa, J. M., and Emerson, B. M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell, 8: 57-69, 2001.
39. Toi, M., Bicknell, R., and Harris, A. L. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res., 52: 275-279, 1992.
40. Obiri, N. I., Hillman, G. G., Haas, G. P., Sud, S., and Puri, R. K. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J. Clin. Invest., 91: 88-93, 1993.
41. Lahm, H., Schnyder, B., Wyniger, J., Borbenyi, Z., Yilmaz, A., Car, B. D., Fischer, J. R., Givel, J. C., and Ryffel, B. Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors. Int. J. Cancer, 59: 440-447, 1994.
42. Topp, M. S., Papadimitriou, C. A., Eitelbach, F., Koenigsmann, M., Oelmann, E., Koehler, B., Oberberg, D., Reufi, B., Stein, H., and Thiel, E. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res., 55: 2173-2176, 1995.
43. Gooch, J. L., Lee, A. V., and Yee, D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res., 58: 4199-4205, 1998.
44. Fontemaggi, G., Kela, I., Amariglio, N., Rechavi, G., Krishnamurthy, J., Strano, S., Sacchi, A., Givol, D., and Blandino, G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J. Biol. Chem., 277: 43359-43368, 2002.
45. Qian, H., Wang, T., Naumovski, L., Lopez, C. D., and Brachmann, R. K. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene, 21: 7901-7911, 2002.
46. Chen, X., Zheng, Y., Zhu, J., Jiang, J., and Wang, J. p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene, 20: 769-774, 2001.
47. Paul, W. E. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood, 77: 1859-1870, 1991.
48. Idzerda, R. L., March, C. J., Mosley, B., Lyman, S. D., Vanden Bos, T., Gimpel, S. D., Din, W. S., Grabstein, K. H., Widmer, M. B., and Park, L. S. Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J. Exp. Med., 171: 861-873, 1990.
49. Kondo, M., Takeshita, T., Ishii, N., Nakamura, M., Watanabe, S., Arai, K., and Sugamura, K. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science (Wash. DC), 262: 1874-1877, 1993.
50. Russell, S. M., Keegan, A. D., Harada, N., Nakamura, Y., Noguchi, M., Leland, P., Friedmann, M. C., Miyajima, A., Puri, R. K., Paul, W. E., and Leonard, W. J. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science (Wash. DC), 262: 1880-1883, 1993.
51. Hilton, D. J., Zhang, J. G., Metcalf, D., Alexander, W. S., Nicola, N. A., and Willson, T. A. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. USA, 93: 497-501, 1996.
52. Kawakami, K., Kawakami, M., Leland, P., and Puri, R. K. Internalization property of' interleukin-4 receptor alpha chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells. Clin. Cancer Res., 8: 258-266, 2002.
53. Murata, T., Obiri, N. I., and Puri, R. K. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors. Int. J. Mol. Med., 1: 551-557, 1998.
54. Robinson, D. S., Hamid, Q., Ying, S., Tsicopoulos, A., Barkans, J., Bentley, A. M., Corrigan, C., Durham, S. R., and Kay, A. B. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med., 326: 298-304, 1992.
55. Rivas, D., Mozo, L., Zamorano, J., Gayo, A., Torre-Alonso, J. C., Rodriguez, A., and Gutierrez, C. Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patients. J. Autoimmun., 8: 587-600, 1995.
56. Morris, L., Troutt, A. B., Handman, E., and Kelso, A. Changes in the precursor frequencies of IL-4 and IFN-gamma secreting CD4+ cells correlate with resolution of lesions in murine cutaneous leishmaniasis. J. Immunol., 149: 2715-2721, 1992.
57. Urban, J. F., Jr., Noben-Trauth, N., Donaldson, D. D., Madden, K. B., Morris, S. C., Collins, M., and Finkelman, F. D. IL-13, IL-4Rα, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity, 8: 255-264, 1998.
58. Afanasyeva, M., Wang, Y., Kaya, Z., Park, S., Zilliox, M. J., Schofield, B. H., Hill, S. L., and Rose, N. R. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am. J. Pathol., 159: 193-203, 2001.
59. Crawford, R. M., Finbloom, D. S., Ohara, J., Paul, W. E., and Meltzer, M. S. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of 1a antigens. J. Immunol., 139: 135-141, 1987.
60. Mule, J. J., Smith, C. A., and Rosenberg, S. A. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J. Exp. Med., 166: 792-797, 1987.
61. Okada, H., and Kuwashima, N. Gene therapy and biologic therapy with interleukin-4. Curr. Gene Ther., 2: 437-450, 2002.
62. Topp, M. S., Papadimitriou, C. A., Eitelbach, F., Oelmann, E., Koehler, B., Oberberg, D., Von Marschall, Z., Reufi, B., Stein, H., and Thiel, E. Antiproliferative effect of human interleukin-4 in human cancer cell lines: studies on the mechanism. Leuk. Lymphoma, 19: 319-328, 1995.
63. Kawakami, M., Kawakami, K., Stepensky, V. A., Maki, R. A., Robin, H., Muller, W., Husain, S. R., and Puri, R. K. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin. Cancer Res., 8: 3503-3511, 2002.
64. Strome, S. E., Kawakami, K., Alejandro, D., Voss, S., Kasperbauer, J. L., Salomao, D., Chen, L., Maki, R. A., and Puri, R. K. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. Clin. Cancer Res., 8: 281-286, 2002.